Upadacitinib

Pre-clinicalRecruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondylarthritis (r-axSpA)

Conditions

Axial Spondylarthritis (r-axSpA)

Trial Timeline

Nov 22, 2021 → Jun 1, 2026

NCT ID

NCT05094128

About Upadacitinib

Upadacitinib is a pre-clinical stage product being developed by AbbVie for Axial Spondylarthritis (r-axSpA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05094128. Target conditions include Axial Spondylarthritis (r-axSpA).

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondylarthritis (r-axSpA) were approved

Approved (6) Terminated (1) Active (14)

🔄Brodalumab + PlaceboKyowa KirinPhase 3

🔄Ixekizumab + PlaceboEli LillyPhase 3

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

✅AdalimumabAbbVieApproved

🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3

🔄adalimumab + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04159597	Pre-clinical	Active	—	—	Crohn Disease
NCT06332534	Phase 3	Recruiting	Jul 26, 2024	Dec 1, 2034	Crohn's Disease
NCT06773403	Approved	Recruiting	Apr 9, 2024	Jan 1, 2026	Prurigo Nodularis
NCT05782907	Phase 3	Active	Nov 6, 2023	Oct 1, 2033	Ulcerative Colitis
NCT05507580	Approved	Completed	May 29, 2023	Aug 15, 2024	Atopic Dermatitis
NCT05094128	Pre-clinical	Recruiting	Nov 22, 2021	Jun 1, 2026	Axial Spondylarthritis (r-axSpA)
NCT04195698	Phase 3	Completed	Jan 15, 2020	Sep 11, 2023	Atopic Dermatitis
NCT03725007	Phase 1	Active	Jun 24, 2019	May 1, 2027	Juvenile Idiopathic Arthritis (JIA)

Competing Products

20 competing products in Axial Spondylarthritis (r-axSpA)

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31